Breaking News Instant updates and real-time market news.

MRK

Merck

$63.83

1.055 (1.68%)

, BMY

Bristol-Myers

$50.48

-4.95 (-8.93%)

10:39
10/10/16
10/10
10:39
10/10/16
10:39

Bristol-Myers tumbles, levels to watch

The stock was last down over 9.6% to $50.07. At that price next support is at $49.34, which would be a fresh 52-week low. Resistance is at $50.85.

MRK

Merck

$63.83

1.055 (1.68%)

BMY

Bristol-Myers

$50.48

-4.95 (-8.93%)

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

MRK Merck
$63.83

1.055 (1.68%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
BMY Bristol-Myers
$50.48

-4.95 (-8.93%)

09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

FDX

FedEx

$189.58

0.61 (0.32%)

17:37
04/26/17
04/26
17:37
04/26/17
17:37
Hot Stocks
FedEx awarded $2.35B government contract »

Federal Express Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 09

    May

  • 09

    May

TCB

TCF Financial

$17.24

0.21 (1.23%)

17:36
04/26/17
04/26
17:36
04/26/17
17:36
Hot Stocks
TCF Financial to change NYSE ticker to 'TCF' from 'TCB' »

TCF Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    Jun

UPL

Ultra Petroleum

$11.17

0.2 (1.82%)

17:34
04/26/17
04/26
17:34
04/26/17
17:34
Syndicate
Breaking Syndicate news story on Ultra Petroleum »

Ultra Petroleum files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

CAVM

Cavium

$70.93

-0.31 (-0.44%)

17:33
04/26/17
04/26
17:33
04/26/17
17:33
Earnings
Cavium sees Q2 adjusted EPS 64c-66c, consensus 62c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

  • 17

    May

RICK

RCI Hospitality

$17.16

0.29 (1.72%)

17:29
04/26/17
04/26
17:29
04/26/17
17:29
Hot Stocks
RCI Hospitality acquires assets of St. Louis real estate and gentlemen's club »

RCI Hospitality acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

MTGE

MTGE Investment Corp.

$17.85

0.15 (0.85%)

, AGNC

AGNC Investment

$20.80

-0.07 (-0.34%)

17:27
04/26/17
04/26
17:27
04/26/17
17:27
Hot Stocks
AGNC Investment may invest in MTGE Investment Corp. common stock »

AGNC Investment's…

MTGE

MTGE Investment Corp.

$17.85

0.15 (0.85%)

AGNC

AGNC Investment

$20.80

-0.07 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 04

    May

LVS

Las Vegas Sands

$59.26

0.79 (1.35%)

17:26
04/26/17
04/26
17:26
04/26/17
17:26
Hot Stocks
Las Vegas Sands reports Q1 Venetian Macao net revenue down 1.1% to $741M »

Reports Q1 Venetian Macao…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 31

    May

DEI

Douglas Emmett

$38.25

-0.56 (-1.44%)

17:22
04/26/17
04/26
17:22
04/26/17
17:22
Hot Stocks
Douglas Emmett acquires two Santa Monica office buildings for $352.8M »

Douglas Emmett has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 01

    Jun

PEGI

Pattern Energy

$22.24

0.08 (0.36%)

17:21
04/26/17
04/26
17:21
04/26/17
17:21
Hot Stocks
Pattern Energy acquires 324 megawatt Broadview Wind in NM »

Pattern Energy Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 01

    Jun

CSLT

Castlight Health

$4.15

0.05 (1.22%)

17:20
04/26/17
04/26
17:20
04/26/17
17:20
Earnings
Castlight Health sees 2017 non-GAAP EPS (28c)-(24c), consensus (14c) »

Sees 2017 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    Jun

KRA

Kraton Performance

$33.14

-0.26 (-0.78%)

17:20
04/26/17
04/26
17:20
04/26/17
17:20
Hot Stocks
Kraton Performance sees FY17 adjusted EBITDA about $350M »

Expects to reduce net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

KRA

Kraton Performance

$33.14

-0.26 (-0.78%)

17:19
04/26/17
04/26
17:19
04/26/17
17:19
Earnings
Kraton Performance reports Q1 adjusted EPS (15c), consensus (20c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

GG

Goldcorp

$14.53

0.17 (1.18%)

17:18
04/26/17
04/26
17:18
04/26/17
17:18
Earnings
Goldcorp reports Q1 EPS 20c, consensus 8c »

Reports Q1 gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

CSLT

Castlight Health

$4.15

0.05 (1.22%)

17:18
04/26/17
04/26
17:18
04/26/17
17:18
Earnings
Castlight Health reports Q1 non-GAAP EPS (5c), consensus (5c) »

Reports Q1 revenue $27.7,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    Jun

HUBG

Hub Group

$40.15

-0.25 (-0.62%)

17:18
04/26/17
04/26
17:18
04/26/17
17:18
Hot Stocks
Hub Group sees FY17 CapEx $90M-$100M »

Says truck brokerage and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 10

    May

CNI

Canadian National

$72.39

-0.71 (-0.97%)

17:17
04/26/17
04/26
17:17
04/26/17
17:17
Hot Stocks
Canadian National to purchase shares under a specific share repurchase program »

CN announced that it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKG

Packaging Corp.

$94.54

0.18 (0.19%)

17:17
04/26/17
04/26
17:17
04/26/17
17:17
Earnings
Packaging Corp.reports Q1 EPS $1.27, consensus $1.23 »

Reports Q1 revenue $1.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MAA

MAA

$101.00

-0.47 (-0.46%)

17:16
04/26/17
04/26
17:16
04/26/17
17:16
Earnings
MAA sees 2017 EPS $2.54-$2.74, consensus $2.29 »

Sees 2017 FFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MKL

Markel

$978.01

-2.31 (-0.24%)

17:15
04/26/17
04/26
17:15
04/26/17
17:15
Earnings
Markel reports Q1 diluted EPS $3.90, may not compare to consensus $4.80 »

Markel reported book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SSW

Seaspan

$6.56

0.29 (4.63%)

17:15
04/26/17
04/26
17:15
04/26/17
17:15
Earnings
Seaspan reports Q1 normalized EPS 15c, consensus 13c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MAA

MAA

$101.00

-0.47 (-0.46%)

17:14
04/26/17
04/26
17:14
04/26/17
17:14
Earnings
MAA reports Q1 EPS 36c with items, consensus 54c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

INDB

Independent Bank

$66.50

0.7 (1.06%)

17:12
04/26/17
04/26
17:12
04/26/17
17:12
Hot Stocks
Independent Bank says receives all regulatory approvals for Island merger »

Independent Bank and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 18

    May

CRY

CryoLife

$16.75

0.5 (3.08%)

17:11
04/26/17
04/26
17:11
04/26/17
17:11
Earnings
CryoLife sees FY17 adjusted EPS 40c-43c, consensus 41c »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

CRY

CryoLife

$16.75

0.5 (3.08%)

17:10
04/26/17
04/26
17:10
04/26/17
17:10
Earnings
CryoLife reports Q1 adjusted EPS 9c, consensus 4c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

CSV

Carriage Services

$28.82

0.24 (0.84%)

17:09
04/26/17
04/26
17:09
04/26/17
17:09
Earnings
Carriage Services reports Q1 adjusted EPS 45c, consensus 49c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 08

    May

  • 09

    May

  • 10

    May

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.